drugset / Trial / NCT01201694

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

NCT01201694

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable doses of surface-controlled water dispersible curcumin (curcumin) that can be given to patients with advanced cancer. The safety of this drug will also be studied.

Timeline

Start
2011-10
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 100 mg Oral